financetom
TECH
financetom
/
Healthcare
/
TECH
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Bio-Techne CorporationTECH
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
7.78B
Revenue (ttm)
1.20B
Net Income (ttm)
158.10M
Shares Out
158.09M
EPS (ttm)
0.98
PE Ratio
50.11
Forward PE
24.30
Dividend
$0.32 (0.65%)
Ex-Dividend Date
Feb 14, 2025
Volume
962,410
Open
49.26
Previous Close
49.26
Day's Range
48.42 - 49.50
52-Week Range
46.44 - 85.57
Beta
1.45
Analysts
Buy
Price Target
81.25 (+65.03%)
Earnings Date
Apr 30, 2025
Description >

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.

The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.

The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.

Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Latest News >
Critical Insights From Penguin Solutions Analyst Ratings: What You Need To Know
Critical Insights From Penguin Solutions Analyst Ratings: What You Need To Know
Nov 4, 2024
Ratings for Penguin Solutions ( PENG ) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Update: Gold Steady as the Dollar and Yields Recover After U.S. Hiring Plunged in October
Update: Gold Steady as the Dollar and Yields Recover After U.S. Hiring Plunged in October
Nov 4, 2024
02:00 PM EDT, 11/01/2024 (MT Newswires) -- (Updates prices.) Gold was steady midafternoon on Friday as the dollar and yields moved higher, recovering from early drops after the United States reported new hiring plunged in October due to hurricanes and strikes. Gold for December delivery was last seen down US$0.20 to US$2,749.10 per ounce. The U.S. Bureau of Labor Statistics...
Sector Update: Health Care Stocks Higher Friday Afternoon
Sector Update: Health Care Stocks Higher Friday Afternoon
Nov 4, 2024
02:01 PM EDT, 11/01/2024 (MT Newswires) -- Health care stocks were advancing Friday afternoon, with the NYSE Health Care Index rising 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) climbed 1.3%. In corporate news, Cardinal Health ( CAH ) reported fiscal Q1 results that topped Wall Street expectations amid a double-digit...
The Analyst Landscape: 11 Takes On Cipher Mining
The Analyst Landscape: 11 Takes On Cipher Mining
Nov 4, 2024
Throughout the last three months, 11 analysts have evaluated Cipher Mining ( CIFR ) , offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 5 0...
Copyright 2023-2025 - www.financetom.com All Rights Reserved